Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V Humbert

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
ACS Photonics|January 22, 2024
Mechanisms of SARS-CoV-2 Inactivation Using UVC Laser RadiationGeorge Devitt, Peter B Johnson, Niall Hanrahan, et al.
Vaccines|June 13, 2020
Liposomal Formulation of ChimeraT, a Multiple T-Cell Epitope-Containing Recombinant Protein, Is a Candidate Vaccine for Human Visceral LeishmaniasisDaniela P Lage, Patrícia A F Ribeiro, Daniel S Dias, et al.
Experimental Parasitology|December 18, 2020
Ivermectin presents effective and selective antileishmanial activity in vitro and in vivo against Leishmania infantum and is therapeutic against visceral leishmaniasisThiago A R Reis, João A Oliveira-da-Silva, Grasiele S V Tavares, et al.
NPJ Vaccines|August 22, 2020
A candidate vaccine for human visceral leishmaniasis based on a specific T cell epitope-containing chimeric protein protects mice against <i>Leishmania infantum</i> infectionDaniela P Lage, Patrícia A F Ribeiro, Daniel S Dias, et al.
Parasitology Research|October 19, 2021
ChimLeish, a new recombinant chimeric protein evaluated as a diagnostic and prognostic marker for visceral leishmaniasis and human immunodeficiency virus coinfectionNathalia C Galvani, Amanda S Machado, Daniela P Lage, et al.
Medical Microbiology and Immunology|April 19, 2021
Acarbose presents in vitro and in vivo antileishmanial activity against Leishmania infantum and is a promising therapeutic candidate against visceral leishmaniasisRafaella R Costa, João A Oliveira-da-Silva, Thiago A R Reis, et al.
Microbial Pathogenesis|December 9, 2021
Sensitive and specific serodiagnosis of tegumentary leishmaniasis using a new chimeric protein based on specific B-cell epitopes of Leishmania antigenic proteinsNathalia C Galvani, Amanda S Machado, Daniela P Lage, et al.
Experimental Parasitology|December 30, 2021
Flau-A, a naphthoquinone derivative, is a promising therapeutic candidate against visceral leishmaniasis: A preliminary studyDébora V C Mendonça, Grasiele S V Tavares, Isabela A G Pereira, et al.
Microbial Pathogenesis|January 24, 2021
Leishmania eukaryotic elongation Factor-1 beta protein is immunogenic and induces parasitological protection in mice against Leishmania infantum infectionThaís T O Santos, Amanda S Machado, Fernanda F Ramos, et al.
Molecular Diagnosis & Therapy|July 18, 2023
Development of an Affordable ELISA Targeting the SARS-CoV-2 Nucleocapsid and Its Application to Samples from the Ongoing COVID-19 Epidemic in GhanaKesego Tapela, Precious C Opurum, Franklin Y Nuokpem, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
ACS Photonics|January 22, 2024
Mechanisms of SARS-CoV-2 Inactivation Using UVC Laser RadiationGeorge Devitt, Peter B Johnson, Niall Hanrahan, et al.
Vaccines|June 13, 2020
Liposomal Formulation of ChimeraT, a Multiple T-Cell Epitope-Containing Recombinant Protein, Is a Candidate Vaccine for Human Visceral LeishmaniasisDaniela P Lage, Patrícia A F Ribeiro, Daniel S Dias, et al.
Experimental Parasitology|December 18, 2020
Ivermectin presents effective and selective antileishmanial activity in vitro and in vivo against Leishmania infantum and is therapeutic against visceral leishmaniasisThiago A R Reis, João A Oliveira-da-Silva, Grasiele S V Tavares, et al.
NPJ Vaccines|August 22, 2020
A candidate vaccine for human visceral leishmaniasis based on a specific T cell epitope-containing chimeric protein protects mice against <i>Leishmania infantum</i> infectionDaniela P Lage, Patrícia A F Ribeiro, Daniel S Dias, et al.
Parasitology Research|October 19, 2021
ChimLeish, a new recombinant chimeric protein evaluated as a diagnostic and prognostic marker for visceral leishmaniasis and human immunodeficiency virus coinfectionNathalia C Galvani, Amanda S Machado, Daniela P Lage, et al.
Medical Microbiology and Immunology|April 19, 2021
Acarbose presents in vitro and in vivo antileishmanial activity against Leishmania infantum and is a promising therapeutic candidate against visceral leishmaniasisRafaella R Costa, João A Oliveira-da-Silva, Thiago A R Reis, et al.
Microbial Pathogenesis|December 9, 2021
Sensitive and specific serodiagnosis of tegumentary leishmaniasis using a new chimeric protein based on specific B-cell epitopes of Leishmania antigenic proteinsNathalia C Galvani, Amanda S Machado, Daniela P Lage, et al.
Experimental Parasitology|December 30, 2021
Flau-A, a naphthoquinone derivative, is a promising therapeutic candidate against visceral leishmaniasis: A preliminary studyDébora V C Mendonça, Grasiele S V Tavares, Isabela A G Pereira, et al.
Microbial Pathogenesis|January 24, 2021
Leishmania eukaryotic elongation Factor-1 beta protein is immunogenic and induces parasitological protection in mice against Leishmania infantum infectionThaís T O Santos, Amanda S Machado, Fernanda F Ramos, et al.
Molecular Diagnosis & Therapy|July 18, 2023
Development of an Affordable ELISA Targeting the SARS-CoV-2 Nucleocapsid and Its Application to Samples from the Ongoing COVID-19 Epidemic in GhanaKesego Tapela, Precious C Opurum, Franklin Y Nuokpem, et al.
Pageof 3